Y
Yoshikazu Inoue
Researcher at Cincinnati Children's Hospital Medical Center
Publications - 273
Citations - 17662
Yoshikazu Inoue is an academic researcher from Cincinnati Children's Hospital Medical Center. The author has contributed to research in topics: Idiopathic pulmonary fibrosis & Medicine. The author has an hindex of 48, co-authored 233 publications receiving 12648 citations. Previous affiliations of Yoshikazu Inoue include Niigata University.
Papers
More filters
Journal Article
A case of cryptococcal empyema successfully treated by debridement by medical thoracoscopy with local anesthesia
Yu Kurahara,Kazunobu Tachibana,Hiroshi Katsura,Yoshikazu Inoue,Katsuhiro Suzuki,Masanori Kitaichi,Seiji Hayashi +6 more
TL;DR: A 57-year-old man with diabetes mellitus with a mass-like shadow in the right middle lung field and numerous yeast-like fungi in fibrotic and necrotic lesions is described.
Journal ArticleDOI
Morphine for dyspnoea in chronic obstructive pulmonary disease: a before-after efficacy study.
Yoshinobu Matsuda,Tatsuya Morita,Hirotaka Matsumoto,Keita Hosoi,Kayo Kusama,Yasuo Kohashi,Hiroshi Morishita,Sawako Kaku,Keisuke Ariyoshi,Shunsuke Oyamada,Yoshikazu Inoue,Satoru Iwase,Takuhiro Yamaguchi,Mitsunori Nishikawa +13 more
TL;DR: Oral morphine is effective in alleviating dyspnoea in Japanese COPD patients and there were no apparent changes in the mean scores of the opioid-related AEs and vital signs.
Journal ArticleDOI
S12 Effect Of Baseline Fvc On Decline In Lung Function With Nintedanib: Results From The Inpulsis™ Trials
Ulrich Costabel,Yoshikazu Inoue,Luca Richeldi,Harold R. Collard,Susanne Stowasser,I. Tschoepe,Arata Azuma +6 more
TL;DR: A subgroup analysis of pooled data from the INPULSIS™ trials showed that nintedanib 150 mg twice daily slowed the decline in lung function in patients with IPF, independent of severity of lung function impairment at baseline.
Journal ArticleDOI
Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient.
Shiomi Yoshida,Tomotada Iwamoto,Kentaro Arikawa,Tsuyoshi Sekizuka,Makoto Kuroda,Yoshikazu Inoue,Satoshi Mitarai,Taisuke Tsuji,Kazunari Tsuyuguchi,Katsuhiro Suzuki +9 more
TL;DR: This is the first case showing the emergence and dominance of Mycobacterium tuberculosis with uncommon rpoB and gyrA mutations, followed by an rpoC compensatory mutation, during treatment of TB.